Helix BioPharma Corp. HBP
TSX · Kanada · Sağlık Teknolojisi
CAD 0,9500+0,04 (+%4,40)
Piyasa kapalı· · CAD · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Piyasa kapalı· · CAD · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
VANCOUVER, BRITISH COLUMBIA - September 28, 2026 (NEWMEDIAWIRE) - Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCF", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company developing novel therapies for difficult-to-treat...
VANCOUVER, BC - August 17, 2026 (NEWMEDIAWIRE) - Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCF", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company developing novel therapies for difficult-to-treat cancers, today a...
VANCOUVER, BRITISH COLUMBIA - August 14, 2026 (NEWMEDIAWIRE) - Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company developing novel therapies for difficult-to-treat ca...
VANCOUVER, BC - June 30, 2026 (NEWMEDIAWIRE) - Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincib...
VANCOUVER, BC - June 12, 2026 (NEWMEDIAWIRE) - Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincib...
VANCOUVER, BC - June 11, 2026 (NEWMEDIAWIRE) - Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincib...
VANCOUVER, BC - June 3, 2026 (NEWMEDIAWIRE) - Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCF", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincibl...
TORONTO, ONTARIO - May 22, 2026 (NEWMEDIAWIRE) - Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vinc...
TORONTO, ONTARIO - May 13, 2026 (NEWMEDIAWIRE) - Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vinc...
TORONTO, ONTARIO - February 24, 2026 (NEWMEDIAWIRE) - Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are...
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.